Bridging preclinical discoveries with human applications is a major hurdle in developing personalized therapies for anemia. Beyond safety and efficacy validation, steps such as biomarker identification, genetic profiling, dose optimization, and stratified clinical trial designs are crucial for tailoring interventions. Using botanicals like Carica papaya as potential hematopoietic agents raises the question of how best to structure this translational pathway.